UKCPA and British Society for Heart Failure publish guidance on Metolazone

7, Dec 2022 News
Share

The UKCPA Heart Failure Committee and the British Society for Heart Failure have published prescribing advice on a new licensed product of metolazone – Xaqua -, including the rationale for prescribing this instead of the unlicensed metolazone product.

The advisory statement also includes information on the product’s bioavailability, potential allergies and intolerance, and advice and actions for clinical practitioners.

The prescribing advice can be viewed or downloaded here.